RecruitingPhase 1Phase 2NCT07469475

Effect of a Daily Supplement on Plasma PAI-1 Levels

Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial


Sponsor

University of California, Los Angeles

Enrollment

35 participants

Start Date

Feb 24, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients. RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease. In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change with aging or cardiovascular disease and may also be indicative or predictive of an illness.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • People of any gender at least 18 years of age who do not have a history of acute or chronic cardiovascular illnesses are eligible.

Exclusion Criteria9

  • Younger than 18 years of age
  • Currently pregnant (which will be confirmed by pregnancy test for participants capable of pregnancy)
  • Using hormonal birth control
  • Current smoker
  • Allergy to ginger, muira puama, Paullinia cupana, or L-citrulline
  • Previous use of Revactin® or RM
  • History of serious cardiovascular events, including myocardial infarction (heart attack) or stroke
  • History of coronary, cardiac, or carotid surgery such as a stent, heart surgery, or endarterectomy
  • Active cancer of any type other than skin cancer

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTSupplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama

Participants will consume a supplement called RM, which is composed of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.


Locations(2)

UCLA

Los Angeles, California, United States

UCLA The Men's Clinic

Santa Monica, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07469475


Related Trials